<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469127</url>
  </required_header>
  <id_info>
    <org_study_id>145358</org_study_id>
    <nct_id>NCT04469127</nct_id>
  </id_info>
  <brief_title>A Study of AIP-303 in HER2 Positive Breast Cancer and/or Metastatic Breast Cancer Patients</brief_title>
  <acronym>Heroine01</acronym>
  <official_title>A Phase I/II Multicenter, Open-Label Study of AIP-303, for HER2-Positive Unresectable and/or Metastatic Breast Cancer Patients Resistant or Refractory to Trastuzumab or Ado-Trastuzumab and Chemotherapy (Heroine-Breast 01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Imaging Projects, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Postgraduate Institute of Medical and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PositronPharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli studi di Trieste</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Advanced Imaging Projects, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HEROINE-Breast01 study is a Phase I/II clinical study of a new investigational agent,&#xD;
      AIP-303 to help patients with metastatic or unresectable HER2-positive breast cancer and for&#xD;
      women with previously treated HER2 positive breast cancer who have gone through at least two&#xD;
      prior lines of treatment and received other HER-2-targeted drugs, Trastuzumab or&#xD;
      Ado-Trastuzumab and chemotherapy as part of earlier treatments and who have progressed on one&#xD;
      or more available therapies. AIP-303 may help slow down tumor growth and this might improve&#xD;
      outcomes and quality-of-life for these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, Phase I/II, multi-center, open-label study in a total of 150 subjects&#xD;
      with HER2 Positive Breast cancer tumors. Eligible participants will undergo baseline&#xD;
      assessments at enrollment. Study participants be administered therapeutic doses of AIP-303 up&#xD;
      to four treatments spaced 8 weeks apart and a CT scan immediately after. An AIP 301 Ga-68&#xD;
      PET/CT scan will be performed four weeks before and four weeks after the initial dose of the&#xD;
      AIP-303. An IEC will review the protocol and any amendments and advertisements used for&#xD;
      recruitment. The IEC will review the patient information sheet and the informed consent form,&#xD;
      their updates (if any), and any written materials given to the patients. A list of all IECs&#xD;
      to which the protocol has been submitted and the name of the committee chairmen will be&#xD;
      included in the clinical trial report.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific Aim 1</measure>
    <time_frame>6 Months</time_frame>
    <description>Demonstrate safety, tolerability and side-effects of the standard dose of 7.4 GBq (200 mCi). (Phase Ib).&#xD;
Measurements used to assess the safety, tolerability and side-effects profile will include adverse events of any grade, grade 3 and 4 adverse events, withdrawals due to adverse events and dose reductions due to adverse events. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v.5.0) will be used to evaluate AE grade.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific Aim 2</measure>
    <time_frame>6 Months</time_frame>
    <description>1. PFS (Phase Ib/II). Percentage of subjects still alive without disease getting worse or without progression (according to RECIST 5.0 Criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Aim 3</measure>
    <time_frame>6 Months</time_frame>
    <description>2. ORR (Phase II): Percentage of subjects still alive. Percentage of subjects who achieved a best overall response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Aim 4</measure>
    <time_frame>6 Months</time_frame>
    <description>3. Demonstrate Time to Response: Time to response is defined as the time from the start of treatment until first documented evidence of PR or CR (whichever status is recorded first) (Phase Ib/II).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Aim 5</measure>
    <time_frame>6 Months</time_frame>
    <description>4. Demonstrate Duration of Response: [Time Frame: From the first documented evidence of a CR or a PR until the first documented sign of disease progression or death, whichever occurred earlier (up to 180 Days).]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Aim 6</measure>
    <time_frame>6 Months</time_frame>
    <description>5. OS (Phase Ib): Percentage of subjects still alive. Percentage of subjects who achieved best overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HER2 Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIP-303</intervention_name>
    <description>Study participants be administered therapeutic doses of AIP-303 up to four treatments spaced 8 weeks apart and a CT scan immediately after. An AIP 301 Ga-68 PET/CT scan will be performed four weeks before and four weeks after the initial dose of the AIP-303.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Patients with HER2+ metastatic solid tumors (may be 3+ by immunohistochemistry or&#xD;
             with evidence of gene amplification (&gt;2.0) by fluorescence in situ hybridization&#xD;
             (FISH))&#xD;
&#xD;
               -  Currently experiencing tumor progression on active Trastuzumab,&#xD;
                  Ado-Trastuzumab/Taxane and/or standard of care.&#xD;
&#xD;
               -  At least 18 years of age&#xD;
&#xD;
               -  The patient is able and willing to comply with the requirements of this trial&#xD;
                  protocol.&#xD;
&#xD;
               -  Able to provide informed consent. Karnofsky score greater than 50&#xD;
&#xD;
               -  Females of childbearing potential must have a negative pregnancy test at&#xD;
                  screening/ baseline&#xD;
&#xD;
               -  AIP 301 positive scan define by SUV greater than 10.&#xD;
&#xD;
               -  Adequate organ function, defined as:&#xD;
&#xD;
                    1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.&#xD;
&#xD;
                    2. Hemoglobin (Hb) ≥9 g/dl (transfusion or use of EPO is permitted).&#xD;
&#xD;
                    3. Platelets &gt; 100,000/mm3&#xD;
&#xD;
                    4. Creatinine ≤ 1.5 x normal value&#xD;
&#xD;
                    5. AST or ALT ≤ 2.5 x ULN (or ≤5 x ULN in case of liver metastasis)&#xD;
&#xD;
                    6. Alkaline phosphatase ≤2.5 x ULN. Alkaline phosphatase may be more than 2.5 x&#xD;
                       ULN only in the case of bone metastases, and AST and ALT less than 1.5 x&#xD;
                       ULN.&#xD;
&#xD;
                    7. Total bilirubin ≤1.5 mg/dl (higher bilirubin levels are permitted if the&#xD;
                       patient has Gilbert's syndrome).&#xD;
&#xD;
               -  Baseline LVEF ≥50% measured using echocardiogram or equilibrium isotopic&#xD;
                  ventriculography (MUGA).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Must not have HER2+ Brain Mets&#xD;
&#xD;
               -  Serious underlying disease other than HER2+ breast cancer in the opinion of the&#xD;
                  investigator.&#xD;
&#xD;
               -  History of drug addiction within the last 1 year or current drug addiction or use&#xD;
                  of illicit drugs.&#xD;
&#xD;
               -  Any indication of the regular use of more than 40 grams of alcohol every day.&#xD;
&#xD;
               -  Smokers who smoke more than 10 cigarettes per day.&#xD;
&#xD;
               -  Known concurrent acute or chronic viral hepatitis B or C infection or human&#xD;
                  immunodeficiency virus (HIV) infection.&#xD;
&#xD;
               -  Presence or history of active tuberculosis (TB) or latent TB infection, defined&#xD;
                  as 1) a positive QuantiFERON-TB Gold test at Screening, or 2) a positive T-spot&#xD;
                  test within 4 weeks of visit 3 and evidence of current or previous pulmonary&#xD;
                  tuberculosis by chest X-ray within 12 weeks of Visit 3.&#xD;
&#xD;
               -  Positive immunoglobulin M antibody titers in the presence of negative&#xD;
                  immunoglobulin G titers to Epstein-Barr virus (EBV).&#xD;
&#xD;
               -  If clinical suspicion of cytomegalovirus (CMV), cytomegalovirus testing should be&#xD;
                  undertaken. Subjects with intestinal mucosa biopsy positive for cytomegalovirus&#xD;
                  at screening are to be excluded.&#xD;
&#xD;
               -  Currently taking any medications other than those allowed per protocol&#xD;
                  guidelines.&#xD;
&#xD;
               -  Infections (including diverticulitis) requiring treatment with antibiotics,&#xD;
                  antivirals, or antifungals within 14 days prior to Visit.&#xD;
&#xD;
               -  Serum creatinine &gt;3.0 mg/dL (270 μM/L)&#xD;
&#xD;
               -  Known severe allergy or hypersensitivity to IV radiographic contrast.&#xD;
&#xD;
               -  Use of any other investigational product or device within 30 days prior to dosing&#xD;
                  or known requirement for any other investigational agent prior to completion of&#xD;
                  all scheduled study assessments.&#xD;
&#xD;
               -  Patients with a body weight of 400 pounds or more or not able to enter the bore&#xD;
                  of the PET/CT scanner due to BMI, because of the compromise in image quality&#xD;
&#xD;
               -  Inability to complete the needed investigational and standard-of-care imaging&#xD;
                  examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)&#xD;
&#xD;
               -  Recognized concurrent active infection&#xD;
&#xD;
               -  Previous Grade 3 or higher allergic reaction to Trastuzumab or Ado-Trastuzumab&#xD;
                  that resulted in discontinuation of Trastuzumab or Ado-Trastuzumab therapy. Any&#xD;
                  additional medical condition, serious intercurrent illness, or other extenuating&#xD;
                  circumstance that, in the opinion of the Investigator, may significantly&#xD;
                  interfere with study compliance.&#xD;
&#xD;
               -  Moderate to severe anemia (hemoglobin &lt;9 g/dL), or thrombocytopenia (platelet&#xD;
                  count &lt;75,000/μL), or serum creatinine &gt;2 mg/dL.&#xD;
&#xD;
               -  Primary or secondary immunodeficiency including neutropenia (absolute neutrophil&#xD;
                  count &lt;1500/μL); or lymphopenia (absolute lymphocyte count &lt;500/μL).&#xD;
&#xD;
               -  Hepatic enzyme levels more than 5 times upper limit of normal: Known clinically&#xD;
                  relevant chronic liver disease.&#xD;
&#xD;
        Impaired hepatic function in the absence of a diagnosis of primary sclerosing cholangitis&#xD;
        (serum transaminases &gt;2.5 x upper limit of normal [ULN], alkaline phosphatase &gt;2.5 x ULN,&#xD;
        or abnormalities in synthetic liver function tests judged by the investigator to be&#xD;
        clinically significant), or a diagnosis of primary sclerosing cholangitis, serum&#xD;
        transaminases &gt;3 x ULN, alkaline phosphatase &gt;3 x ULN, or abnormalities in synthetic liver&#xD;
        function tests (total bilirubin &gt;1.5 x ULN) judged by the investigator to be clinically&#xD;
        significant.&#xD;
&#xD;
          -  Received any live (attenuated) vaccines within 30 days prior to Visit.&#xD;
&#xD;
          -  Recent treatment with medium-to-high-dose intravenous corticosteroids&#xD;
             (methylprednisolone 60 mg/day or hydrocortisone 300 mg/day) within 8 weeks prior to&#xD;
             Visit or oral corticosteroids of more than 20 mg prednisone (or equivalent) within 30&#xD;
             days prior to Visit.&#xD;
&#xD;
          -  Peptide receptor radionuclide therapy (PRRT) at any time prior to enrolment in the&#xD;
             study.&#xD;
&#xD;
          -  Receipt of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 30&#xD;
             days prior to Visit.&#xD;
&#xD;
          -  Treatment with therapeutic enema or suppository, other than required for endoscopy&#xD;
             preparation, within 14 days prior to the screening endoscopy and during the remainder&#xD;
             of the trial.&#xD;
&#xD;
          -  Patients with any other significant medical, psychiatric, or surgical condition,&#xD;
             currently uncontrolled by treatment, which may interfere with completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Satz, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Advanced Imaging Projects</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stanley Satz, Ph.D.</last_name>
    <phone>561-561 286-6842</phone>
    <email>ssatz@advancedimagingprojects.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rose Satz</last_name>
    <phone>5617578666</phone>
    <email>rsatz@advancedimagingprojects.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Veterans Affairs</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David L Bushnell, M.D.</last_name>
      <phone>319-384-7306</phone>
      <email>david-bushnell@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PositronPharma</name>
      <address>
        <city>Santiago</city>
        <zip>878</zip>
        <country>Chile</country>
      </address>
    </facility>
    <contact>
      <last_name>Horatio Amaral, M.D.</last_name>
      <phone>+56 2 24205137</phone>
      <email>contacto@positronpharma.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Dehli</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>C.S. Bal, M.D./Ph.D.</last_name>
      <email>drcsbal@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical and Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160 012</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Br Mittal, M.D./Ph.D.</last_name>
      <phone>+911722756722</phone>
      <email>brmittal@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Trieste</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniele Generali, M.D.</last_name>
      <phone>+39(0)372408042</phone>
      <email>dgenerali@units.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Witwatersrand</name>
      <address>
        <city>Johannesburg</city>
        <zip>2000</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Mboyo Di-Tamba Vangu, M.D./Ph.D.</last_name>
      <email>Mboyo-Di-Tamba.Vangu@wits.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>John O Prior, M.D.</last_name>
      <phone>+41 21 314 3048</phone>
      <email>John.Prior@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>India</country>
    <country>Italy</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Baum RP, Kulkarni HR, Müller D, Satz S, Danthi N, Kim YS, Brechbiel MW. First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting. Cancer Biother Radiopharm. 2015 May;30(4):152-9. doi: 10.1089/cbr.2014.1747.</citation>
    <PMID>25945808</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim YS, Nwe K, Milenic DE, Brechbiel MW, Satz S, Baidoo KE. Synthesis and characterization of αvβ₃-targeting peptidomimetic chelate conjugates for PET and SPECT imaging. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5517-22. doi: 10.1016/j.bmcl.2012.07.024. Epub 2012 Jul 14.</citation>
    <PMID>22853992</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD is to be shared with researchers</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 Yr.</ipd_time_frame>
    <ipd_access_criteria>Contact Sponsor</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

